苯基丁酸戒断的系统综述:关注并发症、治疗策略及单一物质与多物质戒断
本文为系统综述,检索Ovid/MEDLINE、Web of Science和Science Direct并追溯参考文献,纳入25篇病例报告或会议摘要,描述停用苯基丁酸后的戒断表现与治疗。所有病例均为男性,中位年龄30岁,出现戒断前中位日剂量10 g;戒断症状最快在末次给药后2小时出现,64%在接触医疗后首24小时内戒断严重度进展。癫痫发作2例(8%)、插管6例(24%)、入ICU 11例(44%);单用与合并多物质使用的戒断模式和结局相似。治疗策略差异大,最常用苯二氮䓬类(17例,68%),巴氯芬15例(60%),76%需至少两种药物。
要点
- 戒断症状最快在末次苯基丁酸剂量后2小时出现,出现戒断前中位日剂量10 g(IQR 4.75–21.5 g,范围1–200 g)。
- 64%的患者在接触医疗后首24小时内戒断严重度进展,早期需密切监测。
- 44%入ICU、24%插管、8%出现癫痫发作。
- 最常用药物为苯二氮䓬类(17例,68%),巴氯芬15例(60%),76%需至少两种药物。
- 仅3例(12%)门诊管理且均采用苯基丁酸逐渐减量策略;建议咨询有戒断管理经验的中毒学或成瘾专家。
适用人群与场景
- 停用苯基丁酸后出现戒断的成人患者;纳入的病例均为男性,中位年龄30岁(IQR 23.5–34岁,范围4天–68岁)。
- 戒断前中位日剂量10 g(IQR 4.75–21.5 g,范围1–200 g);最短使用时长(每日2–3 g)为1周。
- 单用苯基丁酸与合并多物质使用者的戒断模式和结局相似。
处置流程与药物剂量
- 仅3例(12%)门诊管理,均采用苯基丁酸逐渐减量策略。
- 所有接受药物辅助戒断的患者均住院管理症状,并接受作用于γ-氨基丁酸受体的药物。
- 最常用药物为苯二氮䓬类,17例(68%)。
- 巴氯芬用于15例(60%),其中12例与γ-氨基丁酸A型受体激动剂联用,2例在苯基丁酸减量期间单用。
- 76%(19例)需要至少两种药物治疗症状。
- 2例在多种药物类别初步稳定后门诊单用巴氯芬,报告不良事件:1例出现癫痫发作,另1例戒断症状复发、恢复使用苯基丁酸并住院接受苯二氮䓬类管理戒断症状。
- 作者认为:苯二氮䓬类或巴比妥类联合辅助巴氯芬似乎是中重度戒断最常用的药物;通过缓慢苯基丁酸减量(联合或不联合辅助γ-氨基丁酸激动剂治疗)的门诊管理可能成功。
- 作者建议:咨询有戒断综合征管理经验的中毒学或成瘾专家。
红旗征与不能漏的情况
- 癫痫发作(2例,8%)、需要插管(6例,24%)、入ICU(11例,44%)。
- 64%的患者在接触医疗后首24小时内戒断严重度进展。
- 2例门诊单用巴氯芬者报告不良事件:1例癫痫发作,1例戒断症状复发并恢复使用苯基丁酸。
研究设计与关键结果
- 系统综述检索获得515篇文章,最终纳入25篇,均为病例报告或已发表的会议摘要。
- 所有病例(100%)均为男性,中位年龄30岁(IQR 23.5–34岁,范围4天–68岁)。
- 出现戒断前中位日剂量10 g(IQR 4.75–21.5 g,范围1–200 g);最短使用时长(每日2–3 g)为1周后出现戒断;戒断症状最快在末次剂量后2小时出现。
- 16例(64%)在接触医疗后首24小时内戒断严重度进展;癫痫发作2例(8%),插管6例(24%),入ICU 11例(44%)。
- 单用苯基丁酸与合并多物质使用者的戒断模式和结局相似。
- 治疗策略差异大:仅3例(12%)门诊管理且均采用苯基丁酸减量;所有药物辅助戒断者均住院并接受作用于γ-氨基丁酸受体的药物;苯二氮䓬类17例(68%),巴氯芬15例(60%)(其中12例与γ-氨基丁酸A型受体激动剂联用,2例在减量期间单用),19例(76%)需至少两种药物。
- 2例门诊单用巴氯芬者报告不良事件:1例癫痫发作,1例戒断症状复发、恢复使用苯基丁酸并住院接受苯二氮䓬类管理戒断症状。
证据类型、等级与局限
- 证据类型:系统综述,纳入文献均为病例报告或会议摘要;病例报告采用Joanna Briggs Institute病例报告 kritikal 评价清单进行评估。
- 局限:手工选择文章可能遗漏相关文献;全部数据来自病例报告,可能存在发表偏倚;因病例报告异质性大,特定治疗策略的结局和有意义结论很少可得;仅报告使用苯基丁酸者可能实际使用多种物质;使用者自述的苯基丁酸剂量可能与未规范产品实际含量不同。
对床旁实践的改变
- 作者认为:识别苯基丁酸戒断患者在早期戒断阶段可能出现症状进行性加重很重要。
- 作者认为:苯二氮䓬类或巴比妥类联合辅助巴氯芬似乎是中重度戒断最常用的药物。
- 作者认为:通过缓慢苯基丁酸减量联合或不联合辅助γ-氨基丁酸激动剂治疗的门诊管理可能成功。
- 作者建议:咨询有戒断综合征管理经验的中毒学或成瘾专家。
- 作者认为:需要大量研究来开发苯基丁酸戒断的分诊方法(如严重度评分、住院与门诊管理)并建立最佳治疗方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Phenibut is an unregulated supplement that acts primarily as a gamma-aminobutyric acid type B receptor agonist. Use of phenibut can lead to dependence and subsequent withdrawal when use is stopped. Phenibut withdrawal can cause severe symptoms such as delirium, hallucinations, and seizures. The purpose of this systematic review is to characterize the natural history of phenibut withdrawal and summarize treatment strategies published in the literature.
METHODS: A systematic review was conducted using the preferred reporting items for systematic reviews and meta-analyses checklist. English language peer-reviewed articles or conference abstracts in humans describing phenibut withdrawal after cessation of use were included. Databases (Ovid/MEDLINE, Web of Science, and Science Direct) and references of included articles were searched. Case reports were appraised using the Joanna Briggs Institute critical appraisal checklist for case reports. Patient demographics and key outcomes, including withdrawal characteristics and treatment characteristics, were collected into a predefined data collection sheet by six independent reviewers.
RESULTS: Search results yielded 515 articles of which 25 were included. All articles were case reports or published conference abstracts. All of the cases (100 percent) involved male patients and the median age was 30 years, (interquartile range 23.5-34 years, range 4 days-68 years). The median daily phenibut dose prior to experiencing withdrawal was 10 g (interquartile range 4.75-21.5 g, range 1-200 g). The shortest duration of phenibut use (2-3 g daily) prior to withdrawal was one week. Withdrawal symptoms occurred as quickly as two hours after the last phenibut dose. Sixteen patients (64 percent) reported progression of withdrawal severity within the first 24 hours of healthcare contact. Seizures were reported in two patients (8 percent), intubation in six patients (24 percent), and intensive care unit admission in 11 patients (44 percent). Withdrawal patterns and outcomes were similar in those using phenibut alone and those with comorbid polysubstance use. Withdrawal treatment strategies varied widely. Only three cases (12 percent) were managed outpatient and all three utilized a phenibut tapering strategy. All patients undergoing medication-assisted abstinence were admitted inpatient for symptom management and received a drug that acts on gamma-aminobutyric acid receptors. The most commonly used medication was a benzodiazepine, reported in 17 cases (68 percent). Nineteen patients (76 percent) required at least two drug therapies to manage symptoms. Baclofen was used in 15 cases (60 percent), primarily in conjunction with gamma-aminobutyric acid type A agonists (12 of 15 cases) or as monotherapy during a phenibut taper (two of 15 cases). Two patients using baclofen monotherapy outpatient, after initial stabilization with multiple drug classes, reported adverse effects. One patient had a seizure and the other experienced recurrent withdrawal symptoms, returned to using phenibut, and was admitted to a hospital for withdrawal symptom management with benzodiazepines.
LIMITATIONS: This review is subject to several limitations. Due to the manual nature of article selection, it is possible relevant articles may not have been included. As the entire data set is comprised of case reports it may suffer from publications bias. Outcomes and meaningful conclusions from specific treatment strategies were rarely available because of the heterogeneous nature of case reports. It is possible those reporting only phenibut use were actually using multiple substances. The doses of phenibut a user believed they were taking may be different from what was present in the unregulated product.
CONCLUSIONS: Phenibut withdrawal appears to have a range of severity. It is important to recognize that patients undergoing phenibut abstinence may have progressive symptom worsening during early withdrawal. All published cases of abrupt phenibut abstinence were admitted inpatients for symptom management. Benzodiazepines or barbiturates with adjunctive baclofen appear to be the most commonly used drugs for moderate to severe withdrawal. Outpatient management via slow phenibut tapers with or without adjunctive gamma-aminobutyric acid agonist therapy may be successful. However, there is no standard treatment, and consultation with experts (e.g., toxicologists, addiction specialists) experienced in managing withdrawal syndromes is recommended. Significant study is warranted to develop methods of triaging phenibut withdrawal (e.g., severity scoring, inpatient versus outpatient management) and creating optimal treatment regimens.
参考来源
- Feldman R, Autry B, Dukes J, et al. A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal. Clin Toxicol (Phila). 2023. PMID: 38112312. doi:10.1080/15563650.2023.2285702
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。